10 completed, 2 withdrawn, 1 terminated. 10 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Withdrawn 2 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow CF101: new trials by email Literature Review of CF101 trials Research Report on CF101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Piclidenoson for Treatment of COVID-19 Piclidenoson, Placebo - COVID-19, Coronavirus Infection | Phase 2 | Completed | Can-Fite BioPharma | 6 | 2021-01-06 | 2022-04-22 |
| Safety &Efficacy of CF101 to Subjects With Uveitis CF101, Placebo - Uveitis, Posterior, Uveitis, Intermediate | Phase 2 | Withdrawn | Can-Fite BioPharma | 2019-01-01 | 2018-02-01 | |
| A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee CF101, Placebo - Osteoarthritis of the Knee | Phase 2 | Withdrawn | Can-Fite BioPharma | 2018-11-01 | 2018-02-01 | |
| CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis CF101 2mg, CF101 3mg, Apremilast 30mg - Plaque Psoriasis | Phase 3 | Completed | Can-Fite BioPharma | 528 | 2018-09-15 | 2022-06-28 |
| CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis CF101 1 mg, CF101 2 mg, Placebo - Rheumatoid Arthritis | Phase 3 | Terminated | Can-Fite BioPharma | 244 | 2017-10-30 | 2020-12-19 |
| Trial of CF101 to Treat Patients With Dry Eye Disease CF101 - Keratoconjunctivitis Sicca | Phase 3 | Completed | Can-Fite BioPharma | 236 | 2011-07-01 | 2022-06-30 |
| Trial of CF101 to Treat Patients With Psoriasis CF101, Placebo - Plaque Psoriasis | Phase 2 / Phase 3 | Completed | Can-Fite BioPharma | 293 | 2011-07-01 | 2020-11-18 |
| Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis CF101, Placebo control - Rheumatoid Arthritis | Phase 2 | Completed | Can-Fite BioPharma | 79 | 2010-10-01 | 2022-05-24 |
| Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure CF101, Placebo for - Ocular Hypertension, Glaucoma | Phase 2 | Completed | Can-Fite BioPharma | 89 | 2010-10-01 | 2022-05-12 |
| Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients CF101, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Can-Fite BioPharma | 253 | 2008-02-01 | 2018-03-29 |
| Safety and Efficacy Study of CF101 to Treat Psoriasis CF101 1mg, CF101 2mg, CF101 4mg - Plaque Psoriasis | Phase 2 | Completed | Can-Fite BioPharma | 76 | 2007-06-01 | 2023-02-08 |
| Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca CF101, Placebo - Keratoconjunctivitis Sicca | Phase 2 | Completed | Can-Fite BioPharma | 80 | 2007-01-01 | 2022-05-09 |
| Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients CF101 - Rheumatoid Arthritis | Phase 2 | Completed | Can-Fite BioPharma | 254 | 2006-06-01 | 2023-09-18 |
Arthritis, Rheumatoid (4) · Dry Eye Syndromes (2) · Keratoconjunctivitis Sicca (2) · Psoriasis (2) · COVID-19 (1) · Coronavirus Infections (1) · Glaucoma (1) · Ocular Hypertension (1) · Osteoarthritis (1) · Osteoarthritis, Knee (1) · Uveitis (1) · Uveitis, Intermediate (1) · Uveitis, Posterior (1)
Can-Fite BioPharma (13)
Israel (13) · Bulgaria (7) · Romania (5) · Poland (4) · Serbia (4) · Bosnia and Herzegovina (2) · Canada (2) · Moldova (2) · Ukraine (2) · United States (2) · Croatia (1) · Czechia (1)
Michael H Silverman, MD (8) · Michael David, MD (2) · Irit Bareket, MD (1) · Zivit Harpaz (1)